LONG-TERM DEBT AND COMMITMENTS (Narrative) (Details) - USD ($)			3 Months Ended
	May 29, 2013	Apr. 09, 2013	Mar. 31, 2017	Mar. 31, 2016	May 21, 2013
FDA Approval Qsymia (PMR and CVOT) Member
Long-term debt
Contractual Obligation Term			5 years
Minimum | FDA Approval Qsymia (PMR and CVOT) Member
Long-term debt
Contractual Obligation			$ 180,000,000
Maximum | FDA Approval Qsymia (PMR and CVOT) Member
Long-term debt
Contractual Obligation			220,000,000
Convertible Senior Notes Due 2020
Long-term debt
Offering amount					$ 220,000,000
Interest rate (as a percent)					4.50%
Increase in debt instrument face amount	$ 30,000,000
Conversion price per share (in dollars per share)	$ 14.86
Net proceeds from offering	$ 241,800,000
Total interest expense recognized			7,900,000	$ 7,200,000
Amortization of debt discount			4,700,000	4,200,000
Amortization of deferred financing costs			247,000	225,000
Senior Secured Notes Due 2018
Long-term debt
Total interest expense recognized			1,000,000	1,200,000
Amortization of deferred financing costs			$ 38,000	$ 76,000
Amount received		$ 50,000,000
Amount received in funding and facility payments		$ 500,000
Amount due as a percentage of net sales, if scheduled quarterly payments are less than 25% of the net sales			25.00%
Make-whole premium ratio			1.03